keyword
MENU ▼
Read by QxMD icon Read
search

colorectal peritoneal metastasis

keyword
https://www.readbyqxmd.com/read/29745097/quality-of-life-after-cytoreductive-surgery-and-hipec-a-single-centre-prospective-study
#1
Nikolaos Kopanakis, Eleftherios-Orestis Argyriou, Dimitra Vassiliadou, Christina Sidera, Maria Chionis, John Kyriazanos, Elias Efstathiou, John Spiliotis
PURPOSE: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has become a crucial method in the management of peritoneal metastasis. This study evaluated the Quality of Life (QoL) post CRS plus HIPEC. METHODS: 80/95 patients underwent CRS plus HIPEC at the Metaxa Cancer Hospital, Piraeus, Greece from 06/2011 to 06/2015 and completed the colorectal version of the Functional Assessment of Cancer Therapy questionnaire (FACTC, version 4) at 1 week pre-operatively and at 1, 3, 6, 12, 18, 24 months post-operatively...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29667123/peritoneal-carcinomatosis-arising-from-rectal-or-colonic-adenocarcinoma-treated-with-cytoreductive-surgery-crs-hyperthermic-intraperitoneal-chemotherapy-hipec-two-different-diseases
#2
M Tonello, G Ortega-Perez, O Alonso-Casado, P Torres-Mesa, G Guiñez, S Gonzalez-Moreno
PURPOSE: Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) has poor survival. Multi-modal treatment including systemic chemotherapy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) can be used in selected patients with curative intent. The majority published works consider PC of CRC origin as a homogenous disease. Aim of this study is to stress the different biological behaviors and survival of PC according to colonic or rectal origin. METHODS: Data of CRS and HIPEC procedures for PC of CRC origin performed at MD Anderson Cancer Center-Madrid (Spain) have been collected, dividing patients into two groups according to colonic or rectal PC...
April 17, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29650943/-a-useful-case-of-photodynamic-diagnosis-of-inferior-vena-cava-invasion-by-pancreatic-head-cancer-using-5-aminolevulinic-acid-5-ala
#3
Toru Mizutani, Yasutoshi Murayama, Hisashi Ikoma, Tomohiro Arita, Toshiyuki Kosuga, Hirotaka Konishi, Ryo Morimura, Atsushi Shiozaki, Yoshiaki Kuriu, Masayoshi Nakanishi, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji
Curative resection is necessary to survival in pancreatic cancer, however after surgery, pathologic examination sometimes diagnoses the remains of cancer at the resected stump. Therefore, it is necessary to evaluate the stump by intraoperative rapid pathological examination. 5-aminolevulinic acid(5-ALA)is an endogenous natural amino acid and precursor of the heme pathway. 5-ALA is metabolized and accumulated as protoporphyrin IX(Pp IX)that is photosensitive substance. 5-ALA mediated photodynamic diagnosis(PDD)(ALA-PDD)has high diagnostic ability...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650838/-two-cases-of-hepatic-encephalopathy-after-chemotherapy-for-metastatic-colorectal-cancer
#4
Tae Matsumura, Shingo Noura, Masaki Hirota, Yuki Ozato, Daiki Marukawa, Takashi Shuto, Arisa Muratsu, Akinobu Yasuyama, Akihiro Takata, Chikato Koga, Chizu Kameda, Masahiro Murakami, Ryohei Kawabata, Junzo Shimizu, Junichi Hasegawa
We reported 2 cases of hepatic encephalopathy after chemotherapy for advanced colorectal cancer. Case 1: A 49-year-old male was diagnosed advanced sigmoid colon cancer with peritoneal dissemination, multiple liver metastasis and multiple osseous metastasis. After resection of primary lesion, we administered mFOLFOX6 plus bevacizumab combination therapy. He was in comatose(Japan coma scale 200)3 days after 2 courses of administration of this regimen. Case 2: A 57-year-old female was diagnosed advanced rectal cancer with multiple huge liver metastasis and multiple osseous metastasis...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29579322/multicentre-study-of-laparoscopic-or-open-assessment-of-the-peritoneal-cancer-index-big-renape
#5
G Passot, F Dumont, D Goéré, C Arvieux, P Rousset, J-M Regimbeau, D Elias, L Villeneuve, O Glehen
BACKGROUND: The peritoneal cancer index (PCI) is a comparative prognostic factor for colorectal peritoneal metastasis (CRPM). The ability of laparoscopy to determine the PCI in consideration of cytoreductive surgery remains undetermined, and this study was designed to compare it with laparotomy. METHODS: A prospective multicentre study was conducted for patients with no known CRPM, but at risk of peritoneal disease. Surgery began with laparoscopic exploration followed by open exploration to determine the PCI...
March 26, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29572704/prognostic-impact-of-r0-resection-and-targeted-therapy-for-colorectal-cancer-with-synchronous-peritoneal-metastasis
#6
Dai Shida, Takefumi Yoshida, Taro Tanabe, Shunsuke Tsukamoto, Hiroki Ochiai, Yukihide Kanemitsu
BACKGROUND: The National Comprehensive Cancer Network guidelines recommend R0 resection and targeted therapy, a combination of cytotoxic and molecular targeted agents, such as bevacizumab, cetuximab, and panitumumab, for colorectal cancer with synchronous peritoneal metastasis (M1c). While these therapeutic strategies are drawing attention, their efficacy has not been fully examined. METHODS: The study population comprised 248 consecutive M1c patients who were treated at the National Cancer Center Hospital from 1997 to 2013...
March 23, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29561282/risk-factors-for-peritoneal-recurrence-in-stage-ii-to-iii-colon-cancer
#7
Shuhei Mayanagi, Kosuke Kashiwabara, Michitaka Honda, Koji Oba, Toru Aoyama, Mitsuro Kanda, Hiromichi Maeda, Chikuma Hamada, Sotaro Sadahiro, Junichi Sakamoto, Shigetoyo Saji, Takaki Yoshikawa
BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort. OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection. DESIGN: This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714)...
March 20, 2018: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/29525466/hepatectomy-increases-metastatic-graft-and-growth-in-an-immunocompetent-murine-model-of-peritoneal-metastases
#8
Rea Lo Dico, Annemilai Tijeras-Raballand, Philippe Bonnin, Jean Marie Launay, Rachid Kaci, Cynthia Pimpie, Brice Malgras, Anthony Dohan, Gianluigi Maria Lo Dico, Marc Pocard
BACKGROUND: Curative surgery of synchronous peritoneal metastases (PM) and colorectal liver metastases (LM) has been recently investigated as feasible option. When synchronous peritoneal and liver resection is not achievable, the sequence of the surgery remains unknown. Our hypothesis was that liver resection (LR) promotes peritoneal growth resulting in a non-resectable PM. We sought to analyse the effects of major LR and liver regeneration after hepatectomy in a murine model of PM and the associated angiogenesis...
January 31, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29510456/prevention-of-peritoneal-recurrence-in-high-risk-colorectal-cancer-and-evidence-of-t4-status-as-a-potential-risk-factor
#9
REVIEW
Lee Shyang Kyang, Sarah J Valle, Nayef A Alzahrani, David L Morris
Peritoneal metastasis (PM) following primary resection of colorectal cancer is common. The combined use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy has significantly improved the survival outcome of patients with colorectal PM (CRPM). Diagnosing and treating early PM is essential as its extent is correlated with poorer outcomes. There are two novel therapies - second-look surgery and synchronous hyperthermic intraperitoneal chemotherapy - that are proposed to prophylactically treat or intervene early in the disease process to reduce the incidence and adverse outcomes associated with PM...
March 6, 2018: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/29487003/satb2-is-a-supportive-marker-for-the-differentiation-of-a-primary-mucinous-tumor-of-the-ovary-and-an-ovarian-metastasis-of-a-low-grade-appendiceal-mucinous-neoplasm-lamn-a-series-of-seven-cases
#10
Elisa Schmoeckel, Thomas Kirchner, Doris Mayr
The differentiation between a primary mucinous ovarian neoplasm and an extra-ovarian metastasis in the ovary is often challenging in the histopathologic practice. Among various ovarian metastases from the gastro-intestinal tract the low-grade appendiceal mucinous neoplasm (LAMN) is an important differential diagnosis to consider particularly in case of pseudomyxoma peritonei. A newly recognized marker in the routine diagnostic of a mucinous neoplasm in the ovary is SATB2 (Special AT-rich sequence-binding protein 2)...
March 2018: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29483446/-three-long-surviving-cases-of-peritoneal-metastasis-after-colorectal-cancer-resection
#11
Yoji Nishimura, Shinsuke Kazama, Yusuke Nishizawa, Takashi Takenoya, Michitoshi Takano, Hiroaki Ishii, Yoshiyuki Kawashima, Hirohiko Sakamoto
We experienced 3 impressive colorectal cancer patients who developed peritoneal recurrences and underwent surgery several times and survived for more than 5 years. Case No. 1 was of a 44-year-old woman who underwent right hemicolectomy for her stage II A ascending colon cancer. She developed left ovarian metastasis, which was resected 3 years later. Five years later, she developed a pelvic peritoneal recurrence, which was resected successfully. Thirteen years later, she is doing well. Case No. 2 was of a 61-year-old man who underwent transverse colectomy for his stage II B colon cancer...
February 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29463215/association-of-differential-mirna-expression-with-hepatic-vs-peritoneal-metastatic-spread-in-colorectal-cancer
#12
Sabine Heublein, Markus Albertsmeier, David Pfeifer, Lisa Loehrs, Alexandr V Bazhin, Thomas Kirchner, Jens Werner, Jens Neumann, Martin Kurt Angele
BACKGROUND: Though peritoneal carcinomatosis reflects a late stage of colorectal cancer (CRC), only few patients present with synchronous or metachronous liver metastases alongside their peritoneal carcinomatosis. It is hypothesized that this phenomenon may be causally linked to molecular characteristics of the primary CRC. This study used miRNA profiling of primary CRC tissue either metastasized to the liver, to the peritoneum or not metastasized at all thus to identify miRNAs potentially associated with defining the site of metastatic spread in CRC...
February 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29394827/comprehensive-treatment-using-cytoreductive-surgery-combined-with-perioperative-chemotherapy-improved-outcome-of-colorectal-cancer-patients-with-metachronous-peritoneal-metastasis
#13
Yutaka Yonemura, Emel Canbay, Shouzou Sako, Satoshi Wakama, Haruaki Ishibashi, Masamitsu Hirano, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Kousuke Noguchi, Shunsuke Motoi, Yang Liu, Yan Li, Keizou Taniguchi
To analyze the role of cytoreductive surgery(CRS)plus perioperative chemotherapy on the survival of colorectal cancer(CRC)patients with metachronous peritoneal metastasis(PM). A comprehensive treatment consisting of neoadjuvant chemotherapy plus CRS was performed in 291 CRC patients. Among the 291, 142 and 149 patients had synchronous and metachronous PM, respectively. The results showed no survival difference between the 2 groups. Median survival time(MST)of patients with metachronous PM with complete cytoreduction(CCR-0), small bowel(SB)-PCIC2, PCIC14 and differentiated histologic type ranged from 3...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394749/-a-case-of-colorectal-cancer-with-peritoneal-dissemination-and-liver-metastasis-that-responded-to-comprehensive-treatment-by-chemotherapy-and-crs-plus-hipec
#14
Takuya Fujimoto, Nobuaki Suzuki, Shinobu Tomochika, Hironori Tanaka, Hiroto Matsui, Kazuhiko Sakamoto, Shigeru Takeda, Shigeru Yamamoto, Shigefumi Yoshino, Shoichi Hazama, Haruaki Ishibashi, Yutaka Yonemura, Tomio Ueno, Hiroaki Nagano
We report a case of colorectal cancer with peritoneal dissemination and liver metastasis that achieved R0 resection by preoperative chemotherapy and CRS plus HIPEC. A 33-year-old man presented with a complaint of abdominal bloating. After further examination, he was diagnosed with transverse colon cancer with peritoneal dissemination and liver metastasis. After 9 courses of preoperative XELOX plus cetuximab and 4 courses of preoperative XELIRI plus bevacizumab, he underwent transverse colon resection, peritoneal resection, and HIPEC(MMC 20mg/4,000mL physiological saline, 40mins)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394700/-cell-free-and-concentrated-ascites-reinfusion-therapy-for-malignant-intractable-ascites-from-colorectal-cancer
#15
Katsuya Ohta, Masakazu Ikenaga, Masami Ueda, Ryuji Iwaki, Tae Kinoshita, Kyoko Mishima, Kiyo Shindo, Yoshinao Chinen, Hiroaki Itakura, Takatoshi Takayama, Yujiro Tsuda, Shinsuke Nakashima, Shinichi Adachi, Shunji Endo, Terumasa Yamada
Malignant intractable ascites worsens not only patient symptoms but also their daily activities. It often leads to a patient discontinuing or postponing chemotherapy. In the present study, we introduced cell-free and concentrated ascites reinfusion therapy(CART)for malignant intractable ascites from colorectal cancer. Six patients underwent 12 CART treatments using AHF-WMO as the ascites filterand AHF-UP as the concentrator(Asahi Kasei Medical Co., Ltd.)from January 2014 to January 2017. The patients included 2 men and 4 women aged 67-89 years...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394555/-a-case-of-ascending-colon-cancer-with-synchronous-liver-metastases-and-peritoneal-dissemination
#16
Masato Mito, Hitoshi Kameyama, Yoshifumi Shimada, Saki Yamada, Shinnosuke Hotta, Yuki Hirose, Ryoma Yagi, Yosuke Tajima, Mae Nakano, Takuma Okamura, Masato Nakano, Hiroshi Ichikawa, Masayuki Nagahashi, Jun Sakata, Toshifumi Wakai
The patient was a 73-year-old man with ascending colon cancer and synchronous liver metastases. A right hemicolectomy with a lymph node dissection was performed for the primary lesion. The resected specimen revealed a KRAS codon 12 mutation. After 6 courses of chemotherapy with capecitabine, oxaliplatin, and bevacizumab(Bv), we performed a partial hepatectomy and resection of the peritoneal dissemination. A computed tomography(CT)scan 5 months later revealed the recurrence of the liver metastases. After 8 courses of chemotherapy with 5-fluorouracil, Leucovorin, irinotecan, and Bv, we performed a partial hepatectomy...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29348899/curative-versus-palliative-treatments-for-colorectal-cancer-with-peritoneal-carcinomatosis-a-systematic-review-and-meta-analysis
#17
Wenqiong Wu, Shipeng Yan, Xianzhen Liao, Haifang Xiao, Zhongxi Fu, Lizhang Chen, Jinsong Mou, Haibo Yu, Lian Zhao, Xiangguo Liu
The objective of this study was to provide an up-to-date summary of the current evidence that may be useful for updating guidelines. We comprehensively searched the published literatures and conferences for studies that compared curative with palliative treatments in colorectal cancer patients with peritoneal metastasis. The primary outcomes considered in this study were three- and five-year overall survival rates. We pooled data across studies and estimated summary effect sizes. Overall, patients who received curative treatments had improved three-year survival (hazard ratio (HR), 2...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29328371/cd133-expression-predicts-post-operative-recurrence-in-patients-with-colon-cancer-with-peritoneal-metastasis
#18
Hiroshi Nagata, Soichiro Ishihara, Junko Kishikawa, Hirofumi Sonoda, Koji Murono, Shigenobu Emoto, Manabu Kaneko, Kazuhito Sasaki, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa
Despite extensive research on cancer stem cells in colorectal cancer, the impact of stem cell markers on patient survival remains unclear, particularly in those with distant metastasis. In this study, we focused on colon cancer with peritoneal metastasis and investigated the association between the expression of CD133, aldehyde dehydrogenase-1 (ALDH1) and leucine-rich repeating G-protein coupled receptor-5 (Lgr5), and disease prognosis. Putative stem cell marker expression was immunohistochemically evaluated in samples from 142 primary tumours and 75 peritoneal nodules...
March 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29299357/the-correlations-between-serum-amphiregulin-and-other-clinicopathological-factors-in-colorectal-cancer
#19
Chawalit Chayangsu, Siriporn Khunsri, Virote Sriuranpong, Suebpong Tanasanvimon
Background: Amphiregulin (AREG) is one of the epidermal growth factor receptor (EGFR) ligands and plays the important roles in tumor progression and metastasis. Upregulation of AREG in colorectal cancer (CRC) tissues has been shown to correlate with depth of tumor invasion, nerve invasion and liver metastasis. We sought to investigate a correlation of serum AREG in CRC with clinicopathological parameters. Methods: Patients with CRC receiving treatment at King Chulalongkorn Memorial Hospital during August 2013 to March 2014 were enrolled...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29226856/endocrine-gland-derived-vascular-endothelial-growth-factor-eg-vegf-and-its-receptor-prokr2-are-associated-to-human-colorectal-cancer-progression-and-peritoneal-carcinomatosis
#20
Mohammed Benlahfid, Wael Traboulsi, Frederic Sergent, Mohamed Benharouga, Khalid Elhattabi, Driss Erguibi, Mehdi Karkouri, Hicham Elattar, Abdelaziz Fadil, Yassine Fahmi, Touria Aboussaouira, Nadia Alfaidy
BACKGROUND: The highest risk factor for mortality among malignant tumors is metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor which biological activity is mediated via two G protein-coupled receptors, prokineticin receptor1 (PROKR1) and PROKR2. Recent studies suggested that EG-VEGF expression is deregulated in multiple cancers including colorectal cancer (CRC). METHODS: Using distinctive CRC and peritoneal carcinomatosis (PC) cohorts and a corresponding control cohort, we determined the circulating levels of EG-VEGF and its in situ expression, and that of its related receptors...
February 6, 2018: Cancer Biomarkers: Section A of Disease Markers
keyword
keyword
53496
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"